person · Reporting owner
Lehrer-Graiwer Joshua
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director | April 23, 2026 | May 01, 2026 |
| Global Blood Therapeutics, Inc.GBT · Entity 123220 | Chief Medical Officer | March 05, 2020 | March 09, 2020 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | Director · PRESIDENT AND CEO | February 21, 2023 | February 23, 2023 |
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | President & COO | September 17, 2026 | September 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date April 23, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2036-04-22 | Direct | 64,000 |
Reported balance
After 2026-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-23 · Grant · Acquired 64,000 · Balance 64,000 F1: This option was granted on April 23, 2026 and is scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on April 23, 2026 and is scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.
Global Blood Therapeutics, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,595 |
Ending reported balance
After 2020-03-09 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-03-05 · Sale · Disposed 1,138 · Balance 2,595 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2020-03-09 · Exercise / conversion · Acquired 938 · Balance 3,533 Row 3 · 2020-03-09 · Sale · Disposed 938 · Balance 2,595 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price of the shares sold ranging from $59.80 to $60.00 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.89 · Expires 2026-09-07 | Direct | 1,875 |
Reported balance
After 2020-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-09 · Exercise / conversion · Disposed 938 · Balance 1,875 F3: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price of the shares sold ranging from $59.80 to $60.00 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
LENZ Therapeutics, Inc.
Report date February 21, 2023 · Filed February 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2033-02-20 | Direct | 600,000 |
Reported balance
After 2023-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-21 · Grant · Acquired 600,000 · Balance 600,000 F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
LISATA THERAPEUTICS, INC.
Report date September 17, 2026 · Filed September 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,548 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 21,548 F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,260 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,260 F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements. F3: The shares are held by the Lehrer Family Irrevocable GST Exempt Trust U/A/D November 21, 2025. |
| Series C Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements. |
| Series C Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements. F3: The shares are held by the Lehrer Family Irrevocable GST Exempt Trust U/A/D November 21, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $318.85 · Expires 2034-10-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $318.85 · Expires 2034-10-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $709.69 · Expires 2036-03-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F6: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $5.01 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the closing price on first listing, or the trailing average described above. F7: (continued from Footnote 6) The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement. F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $709.69 · Expires 2036-03-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F8: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $8.35 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the F9: (continued from Footnote 8) closing price on first listing, or the trailing average described above. The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement. F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $545.13 · Expires 2036-03-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F6: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $5.01 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the closing price on first listing, or the trailing average described above. F7: (continued from Footnote 6) The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement. F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $545.13 · Expires 2036-03-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F8: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $8.35 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the F9: (continued from Footnote 8) closing price on first listing, or the trailing average described above. The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement. F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date. F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible
F2: (continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.
F3: The shares are held by the Lehrer Family Irrevocable GST Exempt Trust U/A/D November 21, 2025.
F4: Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date.
F5: Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.
F6: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $5.01 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the closing price on first listing, or the trailing average described above.
F7: (continued from Footnote 6) The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement.
F8: The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $8.35 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the
F9: (continued from Footnote 8) closing price on first listing, or the trailing average described above. The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2026 Filed May 1, 2026 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 64,000 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0001193125-26-201468 · ownership.xml · derivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2036-04-22 F1 · derivative.exercise_date: This option was granted on April 23, 2026 and is scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:02 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-23-012259 · doc4.xml · derivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-02-20 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| February 16, 2022 Filed Feb 19, 2022 00:02 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 650,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-22-011470 · doc4.xml · derivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries B Preferred Stock · Derivative | 19,763 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-027011 · doc4.xml · derivative · entry 8 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 8,126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-027011 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| March 17, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 340,798 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0000899243-21-027011 · doc4.xml · derivative · entry 7 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,798 Underlying: Common Stock · 340,798 shares Expires 2031-03-16 F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F6 · derivative.exercise_date: The option was granted subject to the achievement by the Company of performance vesting criteria. On June 29, 2021 the performance vesting criteria was met such that the option became reportable. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| March 17, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 795,196 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0000899243-21-027011 · doc4.xml · derivative · entry 6 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,196 Underlying: Common Stock · 795,196 shares Expires 2031-03-16 F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| March 11, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantSeries B Preferred Stock · Derivative | 19,763 | $5.06 | $100,000.78 |
DisclosureSEC source: 0000899243-21-027011 · doc4.xml · derivative · entry 5 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,763 Underlying: Common Stock · 8,126 shares Expires not disclosed F3 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F3 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| January 16, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | Exercise / conversionStock Option (right to buy) · Derivative | 374,013 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-21-027011 · doc4.xml · derivative · entry 4 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 374,013 shares Expires 2031-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after April 20, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| January 16, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | Exercise / conversionCommon Stock | 374,013 | $0.30 | $112,203.90 |
DisclosureSEC source: 0000899243-21-027011 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,153,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| January 13, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 374,013 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-21-027011 · doc4.xml · derivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,013 Underlying: Common Stock · 374,013 shares Expires 2031-01-12 F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after April 20, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| March 09, 2020 Filed Mar 9, 2020 19:37 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 938 | $0.00 Strike: $19.89 | $0.00 |
DisclosureSEC source: 0000899243-20-007676 · doc4.xml · derivative · entry 4 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 938 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| March 09, 2020 Filed Mar 9, 2020 19:37 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 938 | $59.90 | $56,186.20 |
DisclosureSEC source: 0000899243-20-007676 · doc4.xml · nonDerivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $59.80 to $60.00 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2020 Filed Mar 9, 2020 19:37 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 938 | $19.89 | $18,656.82 |
DisclosureSEC source: 0000899243-20-007676 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 19:37 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,138 | $65.30 | $74,311.40 |
DisclosureSEC source: 0000899243-20-007676 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007085 · doc4.xml · derivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs shall vest in 8 equal semi-annual installments over 4 years from March 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs shall vest in 8 equal semi-annual installments over 4 years from March 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 612 | $63.96 | $39,143.52 |
DisclosureSEC source: 0000899243-20-007085 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,733 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,750 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-007085 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,313 | $0.00 Strike: $26.90 | $0.00 |
DisclosureSEC source: 0000899243-20-005350 · doc4.xml · derivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 1,313 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,313 | $69.71 | $91,529.23 |
DisclosureSEC source: 0000899243-20-005350 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,313 | $26.90 | $35,319.70 |
DisclosureSEC source: 0000899243-20-005350 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 19:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 625 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0000899243-20-003859 · doc4.xml · derivative · entry 4 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 9, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 19:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 625 | $70.48 | $44,050.00 |
DisclosureSEC source: 0000899243-20-003859 · doc4.xml · nonDerivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 19:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 625 | $12.95 | $8,093.75 |
DisclosureSEC source: 0000899243-20-003859 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 19:49 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 3,937 | $72.40 | $285,038.80 |
DisclosureSEC source: 0000899243-20-003859 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 38,500 | $0.00 Strike: $65.82 | $0.00 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · derivative · entry 14 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 38,500 shares Expires 2030-02-02 F11 · derivative.exercise_date: The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 24,160 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · derivative · entry 13 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,160 Underlying: Common Stock · 24,160 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F10 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F10 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,188 | $0.00 Strike: $48.44 | $0.00 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · derivative · entry 12 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 2,188 shares Expires 2029-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F9 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,657 | $0.00 Strike: $59.60 | $0.00 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · derivative · entry 11 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,250 Underlying: Common Stock · 1,657 shares Expires 2028-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F8 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,657 | $65.00 | $107,705.00 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · nonDerivative · entry 7 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,532 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,657 | $59.60 | $98,757.20 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · nonDerivative · entry 6 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 2,188 | $62.81 | $137,428.28 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · nonDerivative · entry 5 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,532 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 2,188 | $48.44 | $105,986.72 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · nonDerivative · entry 4 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 2,938 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · derivative · entry 10 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,625 Underlying: Common Stock · 2,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F7 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 2,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · derivative · entry 9 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 2,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F6 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 1,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · derivative · entry 8 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,113 Underlying: Common Stock · 1,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from August 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from August 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 2,163 | $65.26 | $141,157.38 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · nonDerivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,532 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,100 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 6,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 20:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 579 | $36.68 | $21,237.72 |
DisclosureSEC source: 0000899243-20-003032 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 16:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 781 | $0.00 Strike: $27.90 | $0.00 |
DisclosureSEC source: 0000899243-20-002292 · doc4.xml · derivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 781 shares Expires 2027-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from July 26, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 16:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 781 | $71.15 | $55,568.15 |
DisclosureSEC source: 0000899243-20-002292 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,016 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 16:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 781 | $27.90 | $21,789.90 |
DisclosureSEC source: 0000899243-20-002292 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 20:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029487 · doc4.xml · derivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On December 13, 2019, the final performance milestone was achieved, resulting in the vesting of the remaining 4,000 shares of Common Stock underlying the RSU grant. F3 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On December 13, 2019, the final performance milestone was achieved, resulting in the vesting of the remaining 4,000 shares of Common Stock underlying the RSU grant. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 20:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 1,984 | $76.88 | $152,529.92 |
DisclosureSEC source: 0000899243-19-029487 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,016 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 20:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-029487 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 17:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 937 | $0.00 Strike: $19.89 | $0.00 |
DisclosureSEC source: 0000899243-19-028940 · doc4.xml · derivative · entry 3 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,813 Underlying: Common Stock · 937 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 17:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 937 | $78.50 | $73,554.50 |
DisclosureSEC source: 0000899243-19-028940 · doc4.xml · nonDerivative · entry 2 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 17:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 937 | $19.89 | $18,636.93 |
DisclosureSEC source: 0000899243-19-028940 · doc4.xml · nonDerivative · entry 1 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 16:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,593 | $0.00 Strike: $59.60 | $0.00 |
DisclosureSEC source: 0000899243-19-028243 · doc4.xml · derivative · entry 24 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,907 Underlying: Common Stock · 11,593 shares Expires 2028-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 16:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 11,593 | $67.19 | $778,933.67 |
DisclosureSEC source: 0000899243-19-028243 · doc4.xml · nonDerivative · entry 16 Lehrer-Graiwer Joshua · CIK 0001789673 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.